Literature DB >> 10730900

Multiple endocrine neoplasia type 1.

A A Pannett1, R V Thakker.   

Abstract

Combined clinical and laboratory investigations of multiple endocrine neoplasia type 1 (MEN1) have resulted in an increased understanding of this disorder which may be inherited as an autosomal dominant condition. Defining the features of each disease manifestation in MEN1 has improved patient management and treatment, and has also facilitated a screening protocol to be instituted. The application of the techniques of molecular biology has enabled the identification of the gene causing MEN1 and the detection of mutations in patients. The function of the protein encoded by the MEN1 gene has been shown to be in the regulation of JunD-mediated transcription but much still remains to be elucidated. However, these recent advances provide for the identification of mutant MEN1 gene carriers who are at a high risk of developing this disorder and thus require regular and biochemical screening to detect the development of endocrine tumours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10730900     DOI: 10.1677/erc.0.0060449

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  30 in total

1.  Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling.

Authors:  H Kaji; L Canaff; J J Lebrun; D Goltzman; G N Hendy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 2.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

Review 3.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

4.  A novel germline mutation of MEN 1 gene in a patient with acromegaly and multiple endocrine tumors.

Authors:  G Pinna; G Orgiana; C Carcassi; F Alba; F Cetani; E Pardi; C Marcocci; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 5.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

6.  The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Authors:  Ya-Xiong Chen; Jizhou Yan; Karen Keeshan; Anthony T Tubbs; Haoren Wang; Albert Silva; Eric J Brown; Jay L Hess; Warren S Pear; Xianxin Hua
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-13       Impact factor: 11.205

7.  A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.

Authors:  J S Crabtree; P C Scacheri; J M Ward; L Garrett-Beal; M R Emmert-Buck; K A Edgemon; D Lorang; S K Libutti; S C Chandrasekharappa; S J Marx; A M Spiegel; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

8.  Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1.

Authors:  Ping La; Yuqing Yang; Satyajit K Karnik; Albert C Silva; Robert W Schnepp; Seung K Kim; Xianxin Hua
Journal:  J Biol Chem       Date:  2007-08-31       Impact factor: 5.157

9.  Menin induces apoptosis in murine embryonic fibroblasts.

Authors:  Robert W Schnepp; Hua Mao; Stephen M Sykes; Wei-Xing Zong; Albert Silva; Ping La; Xianxin Hua
Journal:  J Biol Chem       Date:  2003-12-18       Impact factor: 5.157

10.  Direct binding of DNA by tumor suppressor menin.

Authors:  Ping La; Albert C Silva; Zhaoyuan Hou; Haoren Wang; Robert W Schnepp; Nieng Yan; Yigong Shi; Xianxin Hua
Journal:  J Biol Chem       Date:  2004-08-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.